Molecular genetic characteristics of non-small cell lung cancer using multi-target single-base elongation and fragment analysis
- 作者: Musaelyan A.A1, Nazarov V.D1, Lapin S.V1, Chistyakov I.V1, Komarov I.V1, Tkachenko O.U1, Sogoyan M.V1, Berdnik E.W1, Mazing A.V1, Emanuel W.L1, Akopov A.L1, Orlov S.V1, Bagnenko S.F1
-
隶属关系:
- Pavlov First Saint-Petersburg State Medical University
- 期: 卷 18, 编号 3 (2020)
- 页面: 49-55
- 栏目: Articles
- URL: https://journals.eco-vector.com/1728-2918/article/view/113272
- DOI: https://doi.org/10.29296/24999490-2020-03-06
- ID: 113272
如何引用文章
详细
全文:
作者简介
A. Musaelyan
Pavlov First Saint-Petersburg State Medical University
Email: a.musaelyan8@gmail.com
V. Nazarov
Pavlov First Saint-Petersburg State Medical University
S. Lapin
Pavlov First Saint-Petersburg State Medical University
I. Chistyakov
Pavlov First Saint-Petersburg State Medical University
I. Komarov
Pavlov First Saint-Petersburg State Medical University
O. Tkachenko
Pavlov First Saint-Petersburg State Medical University
M. Sogoyan
Pavlov First Saint-Petersburg State Medical University
E. Berdnik
Pavlov First Saint-Petersburg State Medical University
A. Mazing
Pavlov First Saint-Petersburg State Medical University
W. Emanuel
Pavlov First Saint-Petersburg State Medical University
A. Akopov
Pavlov First Saint-Petersburg State Medical University
S. Orlov
Pavlov First Saint-Petersburg State Medical University
S. Bagnenko
Pavlov First Saint-Petersburg State Medical University
参考
- Bray F., Jacques Ferlay, Isabelle Soerjoma-taram, Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018. https://doi. org/10.3322/caac.21492.
- Arora R., Krishnan V. Selective Targeting of the L858R Mutation (EGFR) in NonSmall Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy. Front Oncol. 2017; 7. https://doi.org/10.3389/ fonc.2017.00104.
- Sokolenko A.P., Imyanitov E.N. Molecular Diagnostics in Clinical Oncology Front Mol. Biosci. 2018; 5: 76. https://doi.org/10.3389/ fmolb.2018.00076.
- Yang Y., Shen X., Li R., Shen J., Zhang H., Yu L. et al. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Oncotarget. 2017. https://doi.org/10.18632/onco-target.17937.
- Лактионов К. К., Артамонова Е. В., Бредер В. В., Горбунова В. А., Моисеенко Ф. В., Реутова Е. В. и соавт. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2018; 8: 30-46.
- Lewandowska M.A., Czubak K., Klonowska K., Jozwicki W, Kowalewski J., Kozlowski P. The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer. PLoS One. 2015. https://doi. org/10.1371/journal.pone.0117983.
- Ettinger D.S., Aisner D.L., Wood D.E., Akerley W, Bauman J., Chang J.Y. et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J. Natl Compr Cancer Netw. 2018. https://doi.org/10.6004/ jnccn.2018.0062.
- O'Kane G.M., Bradbury P.A., Feld R., Leighl N.B., Liu G., Pisters K.M. et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017. https:// doi.org/10.1016/j.lungcan.2017.04.016.
- Lavdovskaia E.D., lyevleva A.G., Sokolenko A.P, Mitiushkina N.V., Preobrazhenskaya E.V, Tiurin VI. et al. EGFR T790M Mutation in TKI-Naive Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts. Oncol Res Treat. 2018. https://doi.org/10.1159/000491441.
- Maus M.K.H., Grimminger P.P., Mack PC., Astrow S.H., Stephens C., Zeger G. et al. KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies. Lung Cancer. 2014; 83: 163-7. https://doi.org/10.10Wj. lungcan.2013.11.010.
- Del Re M., Rofi E., Restante G., Crucitta S., Arrigoni E., Fogli S. et al. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget. 2018. htt-ps://doi.org/10.18632/oncotarget.23553.
- Roman M., Baraibar I., Lopez I., Nadal E., Rolfo C., Vicent S. et al. KrAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target. Mol Cancer 2018. https://doi. org/10.1186/s12943-018-0789-x.
- Planchard D., Popat S., Kerr K., Novello S., Smit E.F, Faivre-Finn C. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upf. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy275.
- Mazeres J., Barlesi F, Filleron T, Besse B., Monnet I., Beau-Faller M. et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: Results from the European EUHER2 cohort. Ann Oncol. 2016. https://doi. org/10.1093/annonc/mdv573.
- Мусаелян А.А., Чистяков И.В., Назаров В.Д., Лапин С.В., Согоян М.В., Хальчицкий С.Е., Эмануэль В.Л., Лобачевская Т.В., Акопов А.Л. Оптимизация метода мультитаргетной однонуклеотидной элонгации для определения соматических мутаций при злокачественных новообразованиях. Молекулярная медицина. 2019; 17 (2): 44-9. https://doi.org/10.29296/24999490-2019-02-06 [Musaelyan A.A., Chistyakov I.V, Nazarov V.D., Lapin S.V, Sogoyan M.V, Khalchitsky S.E., Emanuel W.L., Lobachevskaya T.W., Akopov A.L. Optimization of the method of the multi-target single-base elongation for the detection of somatic mutations in malignancies. Molekulyarnaya meditsina. 2019; 17 (2): 44-9 https://doi. org/10.29296/24999490-2019-02-06 (in Russian)]
- Su Z., Dias-Santagata D., Duke M., Hutchinson K., Lin Y.L., Borger D.R. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagnostics. 2011; 13: 74-84. https://doi.org/10.10Wj. jmoldx.2010.11.010.
- Magnin S., Viel E., Baraquin A., Valmary-Degano S., Kantelip B., Pretet J.-L. et al. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J. Mol. Diagn. 2011. https://doi.org/10.10Wj. jmoldx.2011.05.010.
- Imyanitov N.E., Demidova A.I., Gordiev M., Filipenko M., Kekeyeva V.T., Moliaka K.Y. et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. 2016; 20. https://doi.org/10.1007/s40291-016-0213-4
- Chiu C.H., Yang C.T., Shih J.Y, Huang M.S., Su W.C., Lai R.S. et al. Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J. Thorac. Oncol. 2015. https:// doi.org/10.1097/JTO.0000000000000504
- Lim S.M., Syn N.L., Cho B.C., Soo R.A. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev 2018. https://doi.org/10.10Wj. ctrv. 2018.02.006